MDGL
Madrigal Pharmaceuticals, Inc.$423.25-4.00 (-0.94%)Prev Close$427.39·MCap$9.93B·P/E—·Vol275.3K·Yield—
▲
Buys (12M)
1
$35.02M
▼
Sells (12M)
25
$55.85M
◆
Net Activity
Net Seller
$20.83M
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Madrigal Pharmaceuticals, Inc. (MDGL) has been mixed between buying and selling, with 1 insider purchase totaling $35.02M and 25 insider sales totaling $55.85M. The most recent insider transaction was by Kelley Shannon T (officer: General Counsel), who sold $430.8K worth of shares on Nov 6, 2026. Madrigal Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $9.93B.
MDGL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Kelley Shannon T | officer: General Counsel | Sell | 1,077 | $400.00 | $430.8K | 10,397 |
| Nov 6, 2026 | BAKER BROS. ADVISORS LP | director | Buy | 91,806 | $381.49 | $35.02M | 2,040,682 |
| Sep 11, 2026 | Sibold William John | director, officer: President and CEO | Sell | 11,583 | $538.65 | $6.24M | 209,198 |
| Aug 20, 2026 | Kelley Shannon T | officer: General Counsel | Sell | 664 | $514.97 | $341.9K | 11,474 |
| Jul 20, 2026 | Sibold William John | director, officer: President and CEO | Sell | 2,500 | $547.30 | $1.37M | 211,689 |
| Jun 1, 2026 | Soergel David | officer: Chief Medical Officer | Sell | 1,042 | $495.74 | $516.6K | 10,033 |
| May 22, 2026 | Levy Richard S | director | Sell | 5,642 | $515.50 | $2.91M | 27,337 |
| May 18, 2026 | Soergel David | officer: Chief Medical Officer | Sell | 844 | $515.90 | $435.4K | 11,075 |
| Mar 6, 2026 | Dier Mardi | officer: EVP and CFO | Sell | 1,582 | $429.88 | $680.1K | 13,826 |
| Mar 6, 2026 | Huntsman Carole | officer: Chief Commercial Officer | Sell | 419 | $431.94 | $181.0K | 12,692 |
| Mar 6, 2026 | Kelley Shannon T | officer: General Counsel | Sell | 360 | $431.94 | $155.5K | 12,138 |
| Mar 6, 2026 | Sibold William John | director, officer: President and CEO | Sell | 1,663 | $431.94 | $718.3K | 161,829 |
| Mar 6, 2026 | Taub Rebecca | director | Sell | 491 | $431.94 | $212.1K | 452,213 |
| Mar 2, 2026 | Dier Mardi | officer: EVP and CFO | Sell | 1,183 | $427.21 | $505.4K | 9,257 |
| Jan 26, 2026 | Huntsman Carole | Chief Commercial Officer | Sell | 910 | $493.78 | $449.3K | 0 |
| Jan 26, 2026 | Sibold William John | President and CEO | Sell | 1,577 | $492.42 | $776.5K | 0 |
| Jan 26, 2026 | Taub Rebecca | Director | Sell | 647 | $492.42 | $318.6K | 0 |
| Jan 20, 2026 | Kelley Shannon T | officer: General Counsel | Sell | 692 | $497.36 | $344.2K | 8,910 |
| Jan 20, 2026 | Taub Rebecca | Director | Sell | 2,238 | $490.77 | $1.10M | 0 |
| Jan 13, 2026 | FRIEDMAN PAUL A | director | Sell | 24,440 | $522.59 | $12.77M | 210,204 |
| Jan 13, 2026 | Taub Rebecca | director | Sell | 17,130 | $522.76 | $8.95M | 473,039 |
| Jan 9, 2026 | FRIEDMAN PAUL A | Director | Sell | 280 | $551.24 | $154.3K | 0 |
| Jan 9, 2026 | Taub Rebecca | Director | Sell | 240 | $550.33 | $132.1K | 0 |
| Dec 10, 2025 | FRIEDMAN PAUL A | Director | Sell | 24,800 | $552.19 | $13.69M | 0 |
| Dec 3, 2025 | Sibold William John | President and CEO | Sell | 2,400 | $575.34 | $1.38M | 0 |
| Nov 21, 2025 | Huntsman Carole | Chief Commercial Officer | Sell | 1,958 | $553.11 | $1.08M | 0 |
| Nov 5, 2025 | BATE KENNETH | Director | Sell | 16,575 | $484.30 | $8.03M | 0 |
| Aug 21, 2025 | Sibold William John | President and CEO | Sell | 7,616 | $400.18 | $3.05M | 0 |
| Aug 15, 2025 | BATE KENNETH | Director | Sell | 10,000 | $365.20 | $3.65M | 0 |
| Aug 11, 2025 | FRIEDMAN PAUL A | Director | Sell | 46,808 | $355.31 | $16.63M | 0 |
| Jul 18, 2025 | FRIEDMAN PAUL A | Director | Sell | 1,400 | $350.03 | $490.0K | 0 |
| Jul 16, 2025 | FRIEDMAN PAUL A | Director | Sell | 28,876 | $353.19 | $10.20M | 0 |
| Mar 10, 2025 | Dier Mardi | SVP and CFO | Sell | 258 | $323.04 | $83.3K | 0 |
| Mar 3, 2025 | Huntsman Carole | Chief Commercial Officer | Sell | 1,834 | $325.98 | $597.8K | 0 |
| Feb 27, 2025 | BATE KENNETH | Director | Sell | 20,000 | $356.44 | $7.13M | 0 |
| Jan 27, 2025 | Huntsman Carole | Chief Commercial Officer | Sell | 347 | $335.24 | $116.3K | 10,438 |
| Jan 27, 2025 | Sibold William John | President and CEO | Sell | 1,584 | $335.24 | $531.0K | 54,303 |
| Jan 27, 2025 | Taub Rebecca | Pres., R&D, and CMO | Sell | 648 | $335.24 | $217.2K | 456,662 |
| Jan 27, 2025 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 103 | $335.24 | $34.5K | 4,955 |
| Jan 17, 2025 | Kelley Shannon T | General Counsel | Sell | 277 | $273.41 | $75.7K | 7,705 |
| Jan 17, 2025 | Taub Rebecca | Pres., R&D, and CMO | Sell | 1,689 | $273.41 | $461.8K | 457,310 |
| Jan 17, 2025 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 442 | $273.41 | $120.8K | 5,058 |
| Dec 5, 2024 | CRAVES FRED B | Director | Sell | 3,600 | $315.31 | $1.14M | 11,520 |
| Nov 27, 2024 | CRAVES FRED B | Director | Sell | 3,400 | $350.30 | $1.19M | 15,800 |
| Nov 22, 2024 | Huntsman Carole | Chief Commercial Officer | Sell | 688 | $316.92 | $218.0K | 10,785 |
| Nov 8, 2024 | Levy Richard S | Sell | 5,000 | $350.00 | $1.75M | 11,012-31% | |
| Nov 5, 2024 | Levy Richard S | Sell | 5,000 | $300.94 | $1.50M | 13,212-27% | |
| Sep 11, 2024 | Sibold William John | President and CEO | Sell | 6,363 | $243.83 | $1.55M | 55,887 |
| Jun 18, 2024 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 1,900 | $280.00 | $532.0K | 5,500-26% |
| Jun 14, 2024 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 2,000 | $285.00 | $570.0K | 5,500-27% |
Showing 1–50 of 73
1 / 2
MDGL Insider Buying Activity
The following table shows recent insider purchases of Madrigal Pharmaceuticals, Inc. (MDGL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | BAKER BROS. ADVISORS LP | director | Buy | 91,806 | $381.49 | $35.02M | 2,040,682 |
MDGL Insider Selling Activity
The following table shows recent insider sales of Madrigal Pharmaceuticals, Inc. (MDGL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Kelley Shannon T | officer: General Counsel | Sell | 1,077 | $400.00 | $430.8K | 10,397 |
| Sep 11, 2026 | Sibold William John | director, officer: President and CEO | Sell | 11,583 | $538.65 | $6.24M | 209,198 |
| Aug 20, 2026 | Kelley Shannon T | officer: General Counsel | Sell | 664 | $514.97 | $341.9K | 11,474 |
| Jul 20, 2026 | Sibold William John | director, officer: President and CEO | Sell | 2,500 | $547.30 | $1.37M | 211,689 |
| Jun 1, 2026 | Soergel David | officer: Chief Medical Officer | Sell | 1,042 | $495.74 | $516.6K | 10,033 |
| May 22, 2026 | Levy Richard S | director | Sell | 5,642 | $515.50 | $2.91M | 27,337 |
| May 18, 2026 | Soergel David | officer: Chief Medical Officer | Sell | 844 | $515.90 | $435.4K | 11,075 |
| Mar 6, 2026 | Dier Mardi | officer: EVP and CFO | Sell | 1,582 | $429.88 | $680.1K | 13,826 |
| Mar 6, 2026 | Huntsman Carole | officer: Chief Commercial Officer | Sell | 419 | $431.94 | $181.0K | 12,692 |
| Mar 6, 2026 | Kelley Shannon T | officer: General Counsel | Sell | 360 | $431.94 | $155.5K | 12,138 |
| Mar 6, 2026 | Sibold William John | director, officer: President and CEO | Sell | 1,663 | $431.94 | $718.3K | 161,829 |
| Mar 6, 2026 | Taub Rebecca | director | Sell | 491 | $431.94 | $212.1K | 452,213 |
| Mar 2, 2026 | Dier Mardi | officer: EVP and CFO | Sell | 1,183 | $427.21 | $505.4K | 9,257 |
| Jan 26, 2026 | Huntsman Carole | Chief Commercial Officer | Sell | 910 | $493.78 | $449.3K | 0 |
| Jan 26, 2026 | Sibold William John | President and CEO | Sell | 1,577 | $492.42 | $776.5K | 0 |
| Jan 26, 2026 | Taub Rebecca | Director | Sell | 647 | $492.42 | $318.6K | 0 |
| Jan 20, 2026 | Kelley Shannon T | officer: General Counsel | Sell | 692 | $497.36 | $344.2K | 8,910 |
| Jan 20, 2026 | Taub Rebecca | Director | Sell | 2,238 | $490.77 | $1.10M | 0 |
| Jan 13, 2026 | FRIEDMAN PAUL A | director | Sell | 24,440 | $522.59 | $12.77M | 210,204 |
| Jan 13, 2026 | Taub Rebecca | director | Sell | 17,130 | $522.76 | $8.95M | 473,039 |
| Jan 9, 2026 | FRIEDMAN PAUL A | Director | Sell | 280 | $551.24 | $154.3K | 0 |
| Jan 9, 2026 | Taub Rebecca | Director | Sell | 240 | $550.33 | $132.1K | 0 |
| Dec 10, 2025 | FRIEDMAN PAUL A | Director | Sell | 24,800 | $552.19 | $13.69M | 0 |
| Dec 3, 2025 | Sibold William John | President and CEO | Sell | 2,400 | $575.34 | $1.38M | 0 |
| Nov 21, 2025 | Huntsman Carole | Chief Commercial Officer | Sell | 1,958 | $553.11 | $1.08M | 0 |
| Nov 5, 2025 | BATE KENNETH | Director | Sell | 16,575 | $484.30 | $8.03M | 0 |
| Aug 21, 2025 | Sibold William John | President and CEO | Sell | 7,616 | $400.18 | $3.05M | 0 |
| Aug 15, 2025 | BATE KENNETH | Director | Sell | 10,000 | $365.20 | $3.65M | 0 |
| Aug 11, 2025 | FRIEDMAN PAUL A | Director | Sell | 46,808 | $355.31 | $16.63M | 0 |
| Jul 18, 2025 | FRIEDMAN PAUL A | Director | Sell | 1,400 | $350.03 | $490.0K | 0 |
| Jul 16, 2025 | FRIEDMAN PAUL A | Director | Sell | 28,876 | $353.19 | $10.20M | 0 |
| Mar 10, 2025 | Dier Mardi | SVP and CFO | Sell | 258 | $323.04 | $83.3K | 0 |
| Mar 3, 2025 | Huntsman Carole | Chief Commercial Officer | Sell | 1,834 | $325.98 | $597.8K | 0 |
| Feb 27, 2025 | BATE KENNETH | Director | Sell | 20,000 | $356.44 | $7.13M | 0 |
| Jan 27, 2025 | Huntsman Carole | Chief Commercial Officer | Sell | 347 | $335.24 | $116.3K | 10,438 |
| Jan 27, 2025 | Sibold William John | President and CEO | Sell | 1,584 | $335.24 | $531.0K | 54,303 |
| Jan 27, 2025 | Taub Rebecca | Pres., R&D, and CMO | Sell | 648 | $335.24 | $217.2K | 456,662 |
| Jan 27, 2025 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 103 | $335.24 | $34.5K | 4,955 |
| Jan 17, 2025 | Kelley Shannon T | General Counsel | Sell | 277 | $273.41 | $75.7K | 7,705 |
| Jan 17, 2025 | Taub Rebecca | Pres., R&D, and CMO | Sell | 1,689 | $273.41 | $461.8K | 457,310 |
| Jan 17, 2025 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 442 | $273.41 | $120.8K | 5,058 |
| Dec 5, 2024 | CRAVES FRED B | Director | Sell | 3,600 | $315.31 | $1.14M | 11,520 |
| Nov 27, 2024 | CRAVES FRED B | Director | Sell | 3,400 | $350.30 | $1.19M | 15,800 |
| Nov 22, 2024 | Huntsman Carole | Chief Commercial Officer | Sell | 688 | $316.92 | $218.0K | 10,785 |
| Nov 8, 2024 | Levy Richard S | Sell | 5,000 | $350.00 | $1.75M | 11,012-31% | |
| Nov 5, 2024 | Levy Richard S | Sell | 5,000 | $300.94 | $1.50M | 13,212-27% | |
| Sep 11, 2024 | Sibold William John | President and CEO | Sell | 6,363 | $243.83 | $1.55M | 55,887 |
| Jun 18, 2024 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 1,900 | $280.00 | $532.0K | 5,500-26% |
| Jun 14, 2024 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 2,000 | $285.00 | $570.0K | 5,500-27% |
MDGL Insiders
Similar Stocks to MDGL
VRTX
Vertex Pharmaceuticals Incorporated
$536.14-0.42%
$138.69B
REGN
Regeneron Pharmaceuticals, Inc.
$948.88-0.62%
$99.23B
MRNA
Moderna, Inc.
$214.97-3.55%
$93.61B
RVMD
Revolution Medicines, Inc.
$166.45-3.42%
$39.08B
INSM
Insmed Incorporated
$122.96+1.38%
$26.58B
UTHR
United Therapeutics Corporation
$585.50-0.96%
$25.18B
INCY
Incyte Corporation
$120.12-0.66%
$24.66B
ALNY
Alnylam Pharmaceuticals, Inc.
$159.51-3.31%
$21.41B